Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Parentheticals) (unaudited)

v3.21.1
Condensed Consolidated Balance Sheets (Parentheticals) (unaudited) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Deferred revenue from company clinics attributable to VIE $ 3,045,868 $ 3,000,369
Series A preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Series A preferred stock, shares authorized (in shares) 50,000 50,000
Series A preferred stock, shares issued (in shares) 0 0
Series A preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, shares issued (in shares) 14,288,111 14,174,237
Common stock, shares outstanding (in shares) 14,257,325 14,157,070
Treasury stock, shares (in shares) 30,786 17,167
Variable Interest Entity, Primary Beneficiary    
Deferred revenue from company clinics attributable to VIE $ 2,700,000 $ 2,600,000